Semin Respir Crit Care Med 2012; 33(03): 298-310
DOI: 10.1055/s-0032-1315642
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Community-Acquired Pneumonia Guidelines: A Global Perspective

Michael S. Niederman
1   Department of Medicine, Winthrop University Hospital, Mineola, New York.
2   Department of Medicine, SUNY (State University of New York) at Stony Brook, Stony Brook, New York.
,
Carlos M. Luna
3   Pulmonary Diseases Division, Department of Medicine, Hospital de Clinicas, Buenos Aires, Argentina.
4   Department of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. Juni 2012 (online)

Abstract

Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality worldwide, and since 1993, guidelines for management have been available. The process, which first began in the United States and Canada, has now been implemented in numerous countries throughout the world, and often each geographic region or country develops locally specific recommendations. It is interesting to realize that guidelines from different regions often interpret the same evidence base differently, and guidelines differ from one country to another, even though the bacteriology of CAP is often more similar than different from one region to another. One of the unique contributions of the 2007 US guidelines is the inclusion of quality and performance measures. In addition, US guidelines emphasize management principles that differ from some of the principles in European guidelines because of unique epidemiological considerations. In addition, certain therapy principles apply in the United States that differ from those in other regions, including the need for all patients to receive routine therapy for atypical pathogens, the emergence of community-acquired methicillin-resistant Staphylococcus aureus in some patients following influenza, and the need for all patients admitted to the intensive care unit to receive at least two antimicrobial agents. In the future, as guidelines evolve, there will be an important place for regional guidelines, particularly if these guidelines can recommend locally specific strategies to implement guidelines, which if successful, can lead to improved patient outcomes.

 
  • References

  • 1 World Health Organization, Department of Health Statistics and Informatics. Estimates of Deaths by Cause for the Year 2008. 2008 http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf . Accessed May 30, 2012
  • 2 Niederman MS, Bass Jr JB, Campbell GD , et al; American Thoracic Society. Medical Section of the American Lung Association. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148 (5) 1418-1426
  • 3 Örtqvist A. Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J Suppl 2002; 36: 40s-53s
  • 4 Arnold FW, LaJoie AS, Brock GN , et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009; 169 (16) 1515-1524
  • 5 Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments?. Eur Respir J 2008; 32 (4) 902-910
  • 6 Capelastegui A, España PP, Quintana JM , et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004; 39 (7) 955-963
  • 7 Shorr AF, Bodi M, Rodriguez A, Sole-Violan J, Garnacho-Montero J, Rello J ; CAPUCI Study Investigators. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006; 130 (1) 93-100
  • 8 European Respiratory Society. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11 (4) 986-991
  • 9 Woodhead M, Blasi F, Ewig S , et al; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26 (6) 1138-1180
  • 10 Höffken G, Lorenz J, Kern W , et al; Paul-Ehrlich-Gesellschaft für Chemotherapie; Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin; Deutschen Gesellschaft für Infektiologie und vom Kompetenznetzwerk CAPNETZ. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany [in German]. Pneumologie 2009; 63 (10) e1-e68
  • 11 Alfageme I, Aspa J, Bello S , et al; Grupo de Estudio de la Neumonía Adquirida en la Comunidad. Area de Tuberculosis e Infecciones Respiratorias (TIR)-SEPAR; Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Guidelines for the diagnosis and management of community-acquired pneumonia[in Spanish]. Arch Bronconeumol 2005; 41 (5) 272-289
  • 12 British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 (Suppl. 04) IV1-IV64
  • 13 Sociedade Portuguesa de Pneumologia; Comissão de Infecciologia Respiratória. Portuguese Respiratory Society guidelines for the management of community-acquired pneumonia in immunocompetent adults [in Portuguese]. Rev Port Pneumol 2003; 9 (5) 435-461
  • 14 Société de Pathologie Infectieuse de Langue Francaise. Infections des voies respiratoires, Conférence de consensus en thérapeutique anti-infectieuse. Rev Méd Infect 1991; 21: 1s-8s
  • 15 Chidiac C ; Société de pathologie infectieuse de langue française; Agence française de sécurité sanitaire des produits de santé. Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis [in French]. Med Mal Infect 2011; 41 (5) 221-228
  • 16 Strålin K, Goscinski G, Hedlund J , et al. Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association [in Swedish]. Lakartidningen 2008; 105 (38) 2582-2587
  • 17 Memish ZA, Arabi YM, Ahmed QA, Shibl AM, Niederman MS ; GCC CAP Working Group. Management and prevention strategies for community-acquired pneumonia in the Gulf Corporation Council. J Chemother 2007; 19 (Suppl. 01) 33-46
  • 18 Luna CM, Ramírez J, López H , et al; Grupo de trabajo de la Asociacion Latinoamericana del Tórax (ALAT). ALAT (Latin American Thoracic Association) recommendations on community-acquired pneumonia [in Spanish]. Arch Bronconeumol 2001; 37 (8) 340-348
  • 19 Luna CM, Calmaggi A, Caberloto O , et al; Grupo Argentino de Estudio de la NAC. Neumonia acquired in the community. Practical guide elaborated by a committee intersocieties [in Spanish]. Medicina (B Aires) 2003; 63 (4) 319-343
  • 20 Saldías PF, Pérez CC. National consensus for management of community acquired pneumonia in adults [in Spanish]. Rev Chilena Infectol 2005; 22 (Suppl. 01) S7-s10
  • 21 Corrêa Rde A, Lundgren FL, Pereira-Silva JL , et al; Comissão de Infecções Respiratórias e Micoses - Sociedade Brasileira de Pneumologia e Tisiologia. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. J Bras Pneumol 2009; 35 (6) 574-601
  • 22 Working Group of the South African Thoracic Society. Management of community-acquired pneumonia in adults. S Afr Med J 2007; 97: 1296-1306
  • 23 [(The JRS Guideline for the management of hospital-acquired pneumonia in adults)]. Nippon Naika Gakkai Zasshi 2008; 97 (10) 2578-2583
  • 24 Simpson SH, Marrie TJ, Majumdar SR. Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia. Respir Care Clin N Am 2005; 11 (1) 1-13
  • 25 Bodí M, Rodríguez A, Solé-Violán J , et al; Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005; 41 (12) 1709-1716
  • 26 Menéndez R, Ferrando D, Vallés JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002; 122 (2) 612-617
  • 27 McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Ann Intern Med 2009; 169 (16) 1525-1531
  • 28 Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333 (24) 1618-1624
  • 29 Vergis EN, Yu VL. New directions for future studies of community-acquired pneumonia: optimizing impact on patient care. Eur J Clin Microbiol Infect Dis 1999; 18 (12) 847-851
  • 30 Luna CM, Famiglietti A, Absi R , et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118 (5) 1344-1354
  • 31 Arnold FW, Summersgill JT, Lajoie AS , et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175 (10) 1086-1093
  • 32 World Health Organization, Department of Health Statistics and Informatics. Estimates of Deaths by Cause for the Year 2008. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf . Accessed May 30, 2012
  • 33 Woodhead M, Blasi F, Ewig S , et al; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 2011; 17 (Suppl. 06) E1-E59
  • 34 Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159 (21) 2562-2572
  • 35 Mandell LA, Wunderink RG, Anzueto A , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
  • 36 Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20 (4) 820-837
  • 37 American Thoracic Society. Trends in Pneumonia and Influenza Morbidity and Mortality. American Thoracic Society; 2007
  • 38 Niederman MS, Brito V. Pneumonia in the older patient. Clin Chest Med 2007; 28 (4) 751-771 , vi
  • 39 Fine MJ, Smith MA, Carson CA , et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275 (2) 134-141
  • 40 Feikin DR, Schuchat A, Kolczak M , et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90 (2) 223-229
  • 41 Kaplan V, Clermont G, Griffin MF , et al. Pneumonia: still the old man's friend?. Arch Intern Med 2003; 163 (3) 317-323
  • 42 Baddour LM, Yu VL, Klugman KP , et al; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170 (4) 440-444
  • 43 Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161 (15) 1837-1842
  • 44 Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123 (5) 1503-1511
  • 45 Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005; 128 (2) 940-946
  • 46 Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 1999; 107 (1A) 34S-43S
  • 47 Martin-Loeches I, Lisboa T, Rodriguez A , et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36 (4) 612-620
  • 48 Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119 (5) 1420-1426
  • 49 Farrell DJ, Felmingham D. The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 2005; 56 (4) 795-797
  • 50 Clinical and Laboratory Standards Institute. . Press release. January 2008 www.clsi.org . Accessed May 30, 2012.
  • 51 Plouffe JF, Breiman RF, Facklam RR ; Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 1996; 275 (3) 194-198
  • 52 Metlay JP, Hofmann J, Cetron MS , et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30 (3) 520-528
  • 53 Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29 (2) 321-327
  • 54 Moroney JF, Fiore AE, Harrison LH , et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33 (6) 797-805
  • 55 Daneman N, McGeer A, Green K, Low DE ; Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43 (4) 432-438
  • 56 Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB ; American Thoracic Society. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med 2003; 163 (14) 1718-1726
  • 57 Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A ; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40 (9) 1288-1297
  • 58 Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ ; Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31 (2) 347-382
  • 59 Fine MJ, Auble TE, Yealy DM , et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336 (4) 243-250
  • 60 Lim WS, van der Eerden MM, Laing R , et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58 (5) 377-382
  • 61 Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006; 27 (1) 9-11
  • 62 Aujesky D, Auble TE, Yealy DM , et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118 (4) 384-392
  • 63 Shindo Y, Sato S, Maruyama E , et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology 2008; 13 (5) 731-735
  • 64 Brown SM, Jones BE, Jephson AR, Dean NC ; Infectious Disease Society of America/American Thoracic Society 2007. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009; 37 (12) 3010-3016
  • 65 Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169 (3) 342-347
  • 66 Niederman MS, Brito V. Pneumonia in the older patient. Clin Chest Med 2007; 28 (4) 751-771 , vi
  • 67 File Jr TM, Garau J, Blasi F , et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125 (5) 1888-1901
  • 68 Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128 (1) 172-183
  • 69 Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51 (11) 3977-3982
  • 70 Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010; 138 (1) 130-136
  • 70a Seymann GB. Community-acquired pneumonia: defining quality care. J Hosp Med 2006; 1: 344-353
  • 71 Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164 (6) 637-644
  • 72 Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 2008; 149 (1) 29-32
  • 73 Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008; 168 (4) 351-356
  • 74 Polgreen PM, Chen YY, Cavanaugh JE , et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol 2007; 28 (2) 212-214
  • 75 Whitney CG, Farley MM, Hadler J , et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348 (18) 1737-1746
  • 76 Bender JM, Ampofo K, Korgenski K , et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter?. Clin Infect Dis 2008; 46 (9) 1346-1352
  • 77 Fishbane S, Niederman MS, Daly C , et al. The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med 2007; 167 (15) 1664-1669
  • 78 Woodhead M. Community-acquired pneumonia guidelines—an international comparison: a view from Europe. Chest 1998; 113 (3, Suppl) 183S-187S
  • 79 Díaz A, Barria P, Niederman M , et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131 (3) 779-787